retatrutide phase 3 trials Today, we shared new data from two of retatrutide, our investigational triple agonist. Learn more: https://go.lilly.com/msrz1v Retatrutide FDA Approval Status 2026:

The Impact of Obesity on GLP-1 Levels Obesity is a significant risk factor for developing insulin resistance and type 2 diabetes

If the active compound can penetrate the skin's outer barrier (the stratum corneum) and reach the dermis and subcutaneous tissue, it enters systemic circulation through dermal capillaries without going through your GI tract or liver

Utilising our expertise and experience in medication adherence and patient compliance we acquire, monitor, analyse, guide and interpret data to deliver absolute clarity and bring confidence to sponsors, trialists, and ultimately, patients

Mounjaro is a completely different medication